| January 21, 2026 5:26 pm | — | Barclays | $58.00 | $57.59 | TheFly |
Rapt Therapeutics downgraded to Equal Weight from Overweight at Barclays |
| January 21, 2026 8:57 am | Thomas Smith | Leerink Partners | $58.00 | $57.57 | StreetInsider |
Leerink Partners Downgrades Rapt Therapeutics (RAPT) to Market Perform |
| January 20, 2026 5:48 pm | Yanan Zhu | Wells Fargo | $58.00 | $57.50 | TheFly |
Rapt Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo |
| January 20, 2026 4:55 pm | Emily Bodnar | H.C. Wainwright | $58.00 | $57.51 | TheFly |
Rapt Therapeutics downgraded to Neutral from Buy at H.C. Wainwright |
| January 20, 2026 1:07 pm | — | Piper Sandler | $58.00 | $57.52 | TheFly |
Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler |
| January 9, 2026 10:14 am | — | Piper Sandler | $95.00 | $31.20 | TheFly |
Rapt Therapeutics initiated with an Overweight at Piper Sandler |
| November 3, 2025 11:07 am | — | Wells Fargo | $72.00 | $30.21 | TheFly |
Rapt Therapeutics price target raised to $72 from $48 at Wells Fargo |
| October 27, 2025 3:54 pm | — | H.C. Wainwright | $72.00 | $30.03 | TheFly |
Rapt Therapeutics price target raised to $72 from $27 at H.C. Wainwright |
| October 27, 2025 10:23 am | Yatin Suneja | Guggenheim | $70.00 | $29.53 | TheFly |
Rapt Therapeutics initiated with a Buy at Guggenheim |
| October 13, 2025 9:26 am | — | Barclays | $35.00 | $26.79 | TheFly |
Rapt Therapeutics initiated with an Overweight at Barclays |
